Page last updated: 2024-12-07
viridin
Description
Viridin is a fungal metabolite produced by various species of fungi, including *Trichoderma* and *Aspergillus*. It exhibits a range of biological activities, including antifungal, antibacterial, and antiviral properties. Viridin is known to inhibit the growth of bacteria, yeasts, and molds, and it has been shown to be effective against certain types of cancer cells. The compound is also known to have insecticidal and herbicidal activity. Viridin's biological activity stems from its ability to interfere with the synthesis of proteins and nucleic acids in target organisms. Its unique chemical structure, characterized by a fused pyranone-pyrone ring system, contributes to its biological activity. The biosynthesis of viridin involves a series of enzymatic reactions that are not fully understood. Viridin is a potential lead compound for the development of new drugs with antifungal, antibacterial, and anticancer activities. Research on viridin focuses on understanding its biosynthesis, its mechanism of action, and its potential applications in medicine and agriculture. '
viridin: bacteriocins of alpha-hemolytic streptococcal isolates; RN given refers to (1S-(1alpha,2alpha,11balpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 94257 |
| CHEMBL ID | 2158159 |
| SCHEMBL ID | 150041 |
| MeSH ID | M0058865 |
Synonyms (15)
| Synonym |
|---|
| 18-norandrosta-5,8,11,13-tetraeno[6,5,4-bc]furan-3,7,17-trione, 1-hydroxy-2-methoxy-, (1.beta.,2.beta.)- |
| viridin |
| einecs 221-987-6 |
| x5kjo207mo , |
| unii-x5kjo207mo |
| cyclopenta(7,8)phenanthro(10,1-bc)furan-3,6,9(2h)-trione, 1,7,8,11b-tetrahydro-1-hydroxy-2-methoxy-11b-methyl-, (1s,2r,11bs)- |
| CHEMBL2158159 |
| 1.beta.-hydroxy-2.beta.-methoxy-18-norandrosta-5,8,11,13-tetraeno(6,5,4-bc)furan-3,7,17-trione |
| viridin [mi] |
| SCHEMBL150041 |
| (1r,17s,18s)-18-hydroxy-17-methoxy-1-methyl-13-oxapentacyclo[10.6.1.02,10.05,9.015,19]nonadeca-2(10),3,5(9),12(19),14-pentaene-6,11,16-trione |
| Q21099545 |
| DTXSID00889372 |
| HY-N10189 |
| CS-0372085 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| " In vivo, a SAV dosing of 1 mg/kg once in 48 hours (i." | ( The antiproliferative cytostatic effects of a self-activating viridin prodrug.
Aikawa, E; Blois, J; Cantley, LC; Ellson, C; Figueiredo, JL; Josephson, L; Kohler, R; Smith, A; Weissleder, R; Yaffe, MB; Yuan, H, 2009) | 0.59 |
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 53.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 53.19 (24.57) | | Research Supply Index | 3.30 (2.92) | | Research Growth Index | 4.77 (4.65) | | Search Engine Demand Index | 83.44 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.85%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 25 (96.15%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |